shutterstock_1653845269_taljat_david
Taljat David / Shutterstock.com
11 July 2023GenericsMuireann Bolger

Novartis vows to challenge heart drug patent loss

Decision affects a patent listed in the Orange Book | Generic drug makers have so far failed to secure approval for biosimilar versions of the blockbuster drug.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
18 April 2023   Petition to review invalidation of Gilenya patent denied | Novartis challenged decision resulting from a change in judicial panel.
Big Pharma
17 January 2023   The pharma company’s arguments focusing on ‘inventive step’ failed to convince a London court that the Israeli generic drug maker had infringed, explains Azadeh Vahdat of EIP.

More on this story

Americas
18 April 2023   Petition to review invalidation of Gilenya patent denied | Novartis challenged decision resulting from a change in judicial panel.
Big Pharma
17 January 2023   The pharma company’s arguments focusing on ‘inventive step’ failed to convince a London court that the Israeli generic drug maker had infringed, explains Azadeh Vahdat of EIP.

More on this story

Americas
18 April 2023   Petition to review invalidation of Gilenya patent denied | Novartis challenged decision resulting from a change in judicial panel.
Big Pharma
17 January 2023   The pharma company’s arguments focusing on ‘inventive step’ failed to convince a London court that the Israeli generic drug maker had infringed, explains Azadeh Vahdat of EIP.